4.74
전일 마감가:
$4.79
열려 있는:
$4.79
하루 거래량:
401.04K
Relative Volume:
0.88
시가총액:
$279.35M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
90.46
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
-0.84%
1개월 성능:
+2.82%
6개월 성능:
+7.73%
1년 성능:
-22.93%
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VNDA
Vanda Pharmaceuticals Inc
|
4.74 | 282.30M | 192.64M | 2.51M | 12.42M | 0.0524 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-31 | 개시 | H.C. Wainwright | Buy |
2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
2021-05-12 | 개시 | BofA Securities | Buy |
2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2018-12-04 | 재확인 | Jefferies | Buy |
2018-11-08 | 재개 | Jefferies | Buy |
2018-09-21 | 재개 | Oppenheimer | Outperform |
2018-05-23 | 개시 | Citigroup | Buy |
2018-01-19 | 개시 | Seaport Global Securities | Buy |
2017-09-14 | 재확인 | Piper Jaffray | Overweight |
2017-06-27 | 재개 | Piper Jaffray | Overweight |
2017-05-26 | 개시 | H.C. Wainwright | Buy |
2017-04-12 | 개시 | Oppenheimer | Outperform |
2016-11-09 | 개시 | Aegis Capital | Buy |
2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia
When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com
What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional
What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru
Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks
US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com
Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener
Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus
DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus
Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus
Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News - GuruFocus
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
Vanda Approves Key Proposals at Annual Meeting - TipRanks
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
Judge Favors Vanda But Seeks Deal Over Drug Approval - Law360
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting - PR Newswire
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Justices Urged To Undo Denial Of Fast Track For Gastro Drug - Law360
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):